The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.

J Transl Med · 2018 · PMC6296062 · PMID 30558676

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Development of JAKi with increased activity and/or allosteric inhibition alongside agents with specificity for mutant JAK2 may be significant in the coming years [ 117 , 118 ].

also in 13,097 other papers

may not be significantno p-value reported

However this does not appear to be an observed phenomenon in the clinical trial setting or repeatedly reported and therefore may not be significant.

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.